Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840370 | 0.87 | MMP9 (0.43) | MMELTA4H | |
| SCHEMBL4835104 | 0.81 | HDAC2 (0.39) | HDAC2MMELTA4H | |
| SCHEMBL4840509 | 0.81 | FFAR1 (0.43) | HDAC3HDAC1HDAC2LTA4H | |
| SCHEMBL6252531 | 0.78 | ALDH1A1 (0.49) | HTT | |
| SCHEMBL4843156 | 0.78 | MMP3 (0.42) | HDAC1HDAC2 | |
| SCHEMBL4840468 | 0.77 | MMP3 (0.41) | HDAC3HDAC1HDAC2 | |
| SCHEMBL4838875 | 0.76 | TRPV1 (0.34) | SLC6A9CYP2C9 | |
| SCHEMBL5891859 | 0.75 | PDE4A (0.41) | HDAC1HDAC2HTT | |
| SCHEMBL4841370 | 0.74 | MME (0.47) | MMEHCAR2 | |
| SCHEMBL4835871 | 0.70 | SIGMAR1 (0.48) | MMELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | claimed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | claimed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | claimed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | claimed |
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | HDAC3 2142/4885HDAC1 2219/4885HDAC2 2340/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | HDAC3 2190/4885HDAC1 2179/4885HDAC2 2321/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | HDAC3 2138/4885HDAC1 2079/4885HDAC2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.